Drug class
Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway activator; antioxidant-response modulator
Mechanism of action
Activates the Nrf2 pathway and may suppress pro-inflammatory NF-kB signalling. The precise mechanism by which omaveloxolone improves neurological function in Friedreich ataxia is not fully established; its action is associated with regulation of cellular antioxidant and mitochondrial stress responses.
General use cases
- Treatment of Friedreich ataxia in adults and adolescents aged 16 years and older under the US SKYCLARYS indication; clinical benefit should be interpreted within the approved label and long-term monitoring requirements
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
